[HTML][HTML] Metronomic chemotherapy

ME Cazzaniga, N Cordani, S Capici, V Cogliati, F Riva… - Cancers, 2021 - mdpi.com
Simple Summary The present article reviews the state of the art of metronomic
chemotherapy use to treat the principal types of cancers, namely breast, non-small cell lung …

[HTML][HTML] Immune checkpoint inhibitors in osteosarcoma: A hopeful and challenging future

Z Zhang, X Tan, Z Jiang, H Wang… - Frontiers in Pharmacology, 2022 - frontiersin.org
Osteosarcoma (OS), the most common malignant tumor in the musculoskeletal system,
mainly occurs in adolescents. OS results in high mortality and disability rates due to a fatal …

[HTML][HTML] Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy: A meta-analysis and clinical observation

D Yu, S Zhang, A Feng, D Xu, Q Zhu, Y Mao, Y Zhao… - Medicine, 2019 - journals.lww.com
Background: We designed the study to investigate whether methotrexate, doxorubicin, and
cisplatinum (MAP) chemotherapy strategy was still the preferred option for the survival of …

Optimizing adaptive cancer therapy: dynamic programming and evolutionary game theory

M Gluzman, JG Scott… - Proceedings of the …, 2020 - royalsocietypublishing.org
Recent clinical trials have shown that adaptive drug therapies can be more efficient than a
standard cancer treatment based on a continuous use of maximum tolerated doses (MTD) …

Phase I/II study of palliative triple metronomic chemotherapy in platinum-refractory/early-failure oral cancer

VM Patil, V Noronha, A Joshi, S Dhumal… - Journal of clinical …, 2019 - ascopubs.org
PURPOSE Platinum-resistant oral cancer has a dismal outcome with limited treatment
options. We conducted a phase I/II study to identify the optimal biologic dose (OBD) of …

[HTML][HTML] Osteosarcoma in children: not only chemotherapy

M Argenziano, C Tortora, E Pota, A Di Paola… - Pharmaceuticals, 2021 - mdpi.com
Osteosarcoma (OS) is the most severe bone malignant tumor, responsible for altered
osteoid deposition and with a high rate of metastasis. It is characterized by heterogeneity …

[HTML][HTML] Peroxisome proliferator-activated receptors (PPAR) γ agonists as master modulators of tumor tissue

D Heudobler, M Rechenmacher, F Lüke… - International Journal of …, 2018 - mdpi.com
In most clinical trials, thiazolidinediones do not show any relevant anti-cancer activity when
used as mono-therapy. Clinical inefficacy contrasts ambiguous pre-clinical data either …

[HTML][HTML] Activation of dynamin-related protein 1 and induction of mitochondrial apoptosis by exosome-rifampicin nanoparticles exerts anti-osteosarcoma effect

W Chen, W Lin, N Yu, L Zhang, Z Wu… - International Journal …, 2022 - ncbi.nlm.nih.gov
Activation of Dynamin-Related Protein 1 and Induction of Mitochondrial Apoptosis by
Exosome-Rifampicin Nanoparticles Exerts Anti-Osteosarcoma Effect - PMC Back to Top …

[HTML][HTML] miR-423-5p inhibits osteosarcoma proliferation and invasion through directly targeting STMN1

X Wang, L Peng, X Gong, X Zhang, R Sun… - Cellular Physiology and …, 2018 - karger.com
Background/Aims: Increasing evidences suggest that dysregulated expression of miRNAs
contributes to the progression of various tumors. However, the underlying function of miR …

LncRNA CRNDE is activated by SP1 and promotes osteosarcoma proliferation, invasion, and epithelial‐mesenchymal transition via Wnt/β‐catenin signaling pathway

Q Ding, F Mo, X Cai, W Zhang, J Wang… - Journal of cellular …, 2020 - Wiley Online Library
Long noncoding RNAs (lncRNAs) were identified as a vital part in the development and
progression of cancer in recent years. Colorectal neoplasia differentially expressed …